MMP2 and plasma cell myeloma: Interestingly, Bortezomib (a proteasome inhibitor used in humans as a therapeutic agent for multiple myeloma) has been shown to elicit an anti-fibrosis effect through a dual activity: an increase in MMP1 and MMP2 mRNA and proteins and a decrease in collagen 1a mRNAs and proteins [55].